German CureVac Company predicts that the European Medicines Agency (EMA) will register its vaccine against coronavirus in a few weeks, not later than until the end of June as Augsburger Allgemeine Zeitung reported CureVac Spokesperson Sarah Fakih.
“We expect for the admission to use during the second quarter,” Fakih stated.
The company expects approval by the EMA in June.
According to the company, the number of trials of the vaccine with the use of the modern messenger RNA method showed positive results and much data was provided to the regulator.
A few million doses of the drug were already produced earlier to enable the company to supply it to the market as soon as possible. The EU has already ordered 225 million bottles.
Besides, CureVac is working on the extension of capacities with the growing network of partners.
The company puts high hopes on the development of the vaccine of the second generation together with Glaxo Smith Kline partner. The second vaccine is dedicated to the improvement of immunization, particularly against virus mutations.
The messenger RNA method is also used by BioNTech and Pfizer.
As we reported, Sanofi and GSK announced successful trials of their coronavirus vaccine.